Skip to main content
Lloyd Damon, MD, Oncology, San Francisco, CA, UCSF Medical Center

LloydDamonMD

Oncology San Francisco, CA

Hematologic Oncology

Professor of Medicine, UCSF

Dr. Damon is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

  • Connect with other colleagues in the same hospital or clinic
  • Search all U.S. specialist profiles and refer a patient
  • Read the latest clinical news and earn CME/CEU credits

See Dr. Damon's full profile

Already have an account?

Education & Training

  • University of California (San Francisco)
    University of California (San Francisco)Residency, Internal Medicine, 1982 - 1985
  • University of Michigan Medical School
    University of Michigan Medical SchoolClass of 1982

Certifications & Licensure

  • CA State Medical License
    CA State Medical License 1983 - 2025
  • American Board of Internal Medicine Internal Medicine
  • American Board of Internal Medicine Hematology
  • American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

  • America's Top Doctors Castle Connolly, 2006-2014
  • America's Top Doctors for Cancer Castle Connolly, 2005-2013
  • CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2012-2013
  • Join now to see all

Clinical Trials

Publications & Presentations

PubMed

Abstracts/Posters

  • Direct Oral Anticoagulant Use and Outcomes in Patients with High and Intermediate Risk BCR-ABL-Negative Myeloproliferative Neoplasms
    Lloyd E. Damon, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
  • Blinatumomab in Combination with Pembrolizumab Is Safe for Adults with Relapsed or Refractory B-Lineage Acute Lymphoblastic Leukemia: University of California Hematolo...
    Lloyd E. Damon, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019

Press Mentions

  • BiTEs, CAR T-cell Therapy Enhance ALL Armamentarium, but Questions Remain
    BiTEs, CAR T-cell Therapy Enhance ALL Armamentarium, but Questions RemainJanuary 22nd, 2020
  • OncLive® Announces the Latest State of the Science Summit™ on the Treatment of Hematologic Malignancies
    OncLive® Announces the Latest State of the Science Summit™ on the Treatment of Hematologic MalignanciesSeptember 19th, 2018

Hospital Affiliations